We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Uniphar Plc | LSE:UPR | London | Ordinary Share | IE00BJ5FQX74 | ORD EUR0.08 (CDI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 223.00 | 220.00 | 226.00 | 223.00 | 223.00 | 223.00 | 27,825 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 2.55B | 44.82M | 0.1641 | 13.59 | 608.82M |
Date | Subject | Author | Discuss |
---|---|---|---|
03/2/2023 08:32 | Uniphar Holding(s) in Company | johnwise | |
03/3/2022 10:46 | 03/03/2022 7:31am RNS Number : 5134D Acquisition of Ordinary Shares Uniphar PLC Director/PDMR Shareholding | johnwise | |
01/3/2022 16:03 | Uniphar plc is regarded as a diversified healthcare services in the UK and Republic of Ireland. The company operates through three divisions: Commercial & Clinical, Product Access, and Supply Chain & Retail. The Commercial & Clinical division offers outsourced sales, marketing, and multichannel account management services to pharmaco-medical manufacturers, and distribution and support services to medical device manufacturers. The Product Access division provides on demand services, which provides access to pharmaco-medical products and treatments by developing valuable relationships and interactions between manufacturers and other healthcare stakeholders; and exclusive access services that offers bespoke distribution partnerships to pharmaceutical partners for key brands. The Supply Chain & Retail division engages in pre-wholesale and wholesale distribution of pharmaceutical, healthcare products to pharmacies and hospitals. These highly innovative methodologies and cutting-edge initiatives will be effectively incorporated into the firm’s financial prospects, where net profit soared to £48,122m from £27,811m, thus trading ahead of expectations, thus resulting in a profit growth of 26.3%. Despite the favourable corporate news, the firm is undervalued since it is trading at a P/E ratio of 16.9, which is below the healthcare sector P/E ratio of 26.3. Consequently, it implies that Uniphar plc is expected to surge in value, as illustrated by the robust EPS growth of 16.2% and attractive P/B ratio of 4.08. Keep up to date with WealthOracle AM | km18 | |
01/3/2022 07:59 | 01/03/2022 7:00am RNS Number : 1188D Uniphar PLC 2021 Preliminary Results | johnwise | |
01/2/2021 17:47 | Great company, looking to expand into NA and Europe soon. | kevraff | |
01/2/2021 15:25 | Dublin, London | 20 January 2021: Uniphar plc ("Uniphar" or the "Company") today announces it has applied to the London Stock Exchange to change the currency in which the Company's ordinary shares are traded on the London Stock Exchange from Euro to Sterling. It is expected this change will become effective at 8.00 am on 1 February 2021. | arcadian | |
01/2/2021 14:26 | Whats the story here? | netcurtains | |
01/2/2021 09:02 | is that a very fat finger? | bg23 | |
02/9/2020 07:43 | !FOLLOWFEED | molatovkid |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions